Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad
PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )
20 Sep 2021

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
20 Sep 2021

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
19 Sep 2021

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer

Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )
19 Sep 2021

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )
19 Sep 2021

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
19 Sep 2021

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021

B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )
18 Sep 2021

Cabozantinib in combination with atezolizumab in patients with mCRPC

Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, USA
Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal -  University of Utah School of Medicine, Salt Lake CIty, USA )
18 Sep 2021